The global cannabinoid market is projected to grow from $28.26 billion in 2021 to $197.74 billion in 2028 at a compound annual growth rate, CAGR, of 32.04%. One mature and seasoned company that entered the market in 2016 is Linnea SA.
It is rare to find a company that has decades of experience producing botanical ingredients that is now producing a GMP-certified pharmaceutical-grade CBD for the cannabinoid industry.
Another major opportunity presented by established global companies in the cannabinoid industry relates to setting operation standards on critical issues such as sustainability. Linnea has tremendous respect for the environment in its processes, practicing extreme precision
and commitment to innovation and research. The company also participates in a local sustainability project that has positive social impact on the local people and community. They partner with local farmers in a biogas installation facility converting organic biomass waste into energy and providing electricity for hundreds of homes in their local area of Switzerland.
With the growth of these markets comes increased demand for truly standardized high quality cannabinoid ingredients. Linnea currently sells its botanical ingredients to over 70 countries and serves over 250 large business clients, including some of the most trusted finished product producers in the cannabinoid industry.
It is ultimately medical patients globally that will be the beneficiaries of the industry’s maturation and rapid growth. Having established seasoned pharmaceutical companies like Linnea in the cannabis industry creates substantially more standardization, quality, transparency, stability, and reliability for businesses, patients and consumers.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
